XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.21.2

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2021
Revenue from Contract with Customer [Abstract] |
REVENUES | REVENUES Disaggregation of Revenues Revenues were as follows:
|  | Three Months Ended September 30, 2021 |  | Three Months Ended September 30, 2020 |  |  |  |
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total |  |  |  |
Product Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 21 |  |  | $ | 2 |  |  | $ | 4 |  |  | $ | 27 |  |  | $ | 99 |  |  | $ | 5 |  |  | $ | 9 |  |  | $ | 113 |  |  |  |  |
Biktarvy |  | 1,875 |  |  | 254 |  |  | 147 |  |  | 2,276 |  |  | 1,584 |  |  | 194 |  |  | 113 |  |  | 1,891 |  |  |  |  |
Complera/Eviplera |  | 28 |  |  | 31 |  |  | 5 |  |  | 64 |  |  | 26 |  |  | 35 |  |  | 9 |  |  | 70 |  |  |  |  |
Descovy |  | 355 |  |  | 42 |  |  | 36 |  |  | 433 |  |  | 424 |  |  | 49 |  |  | 35 |  |  | 508 |  |  |  |  |
Genvoya |  | 576 |  |  | 100 |  |  | 68 |  |  | 744 |  |  | 669 |  |  | 116 |  |  | 61 |  |  | 846 |  |  |  |  |
Odefsey |  | 275 |  |  | 112 |  |  | 12 |  |  | 399 |  |  | 309 |  |  | 116 |  |  | 12 |  |  | 437 |  |  |  |  |
Stribild |  | 28 |  |  | 11 |  |  | 3 |  |  | 42 |  |  | 27 |  |  | 13 |  |  | 2 |  |  | 42 |  |  |  |  |
Truvada |  | 55 |  |  | 5 |  |  | 7 |  |  | 67 |  |  | 492 |  |  | 6 |  |  | 11 |  |  | 509 |  |  |  |  |
Revenue share - Symtuza(1) |  | 86 |  |  | 41 |  |  | 3 |  |  | 130 |  |  | 82 |  |  | 34 |  |  | 2 |  |  | 118 |  |  |  |  |
Other HIV(2) |  | 3 |  |  | 4 |  |  | — |  |  | 7 |  |  | 10 |  |  | 1 |  |  | 2 |  |  | 13 |  |  |  |  |
Total HIV |  | 3,302 |  |  | 602 |  |  | 285 |  |  | 4,189 |  |  | 3,722 |  |  | 569 |  |  | 256 |  |  | 4,547 |  |  |  |  |
Hepatitis C virus (“HCV”) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ledipasvir/Sofosbuvir(3) |  | 14 |  |  | 5 |  |  | 26 |  |  | 45 |  |  | 36 |  |  | 11 |  |  | 37 |  |  | 84 |  |  |  |  |
Sofosbuvir/Velpatasvir(4) |  | 173 |  |  | 77 |  |  | 82 |  |  | 332 |  |  | 170 |  |  | 74 |  |  | 86 |  |  | 330 |  |  |  |  |
Other HCV(5) |  | 37 |  |  | 12 |  |  | 3 |  |  | 52 |  |  | 35 |  |  | 13 |  |  | 2 |  |  | 50 |  |  |  |  |
Total HCV |  | 224 |  |  | 94 |  |  | 111 |  |  | 429 |  |  | 241 |  |  | 98 |  |  | 125 |  |  | 464 |  |  |  |  |
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vemlidy |  | 103 |  |  | 9 |  |  | 96 |  |  | 208 |  |  | 99 |  |  | 8 |  |  | 70 |  |  | 177 |  |  |  |  |
Viread |  | 1 |  |  | 7 |  |  | 18 |  |  | 26 |  |  | 3 |  |  | 8 |  |  | 21 |  |  | 32 |  |  |  |  |
Other HBV/HDV(6) |  | — |  |  | 13 |  |  | — |  |  | 13 |  |  | — |  |  | 2 |  |  | — |  |  | 2 |  |  |  |  |
Total HBV/HDV |  | 104 |  |  | 29 |  |  | 114 |  |  | 247 |  |  | 102 |  |  | 18 |  |  | 91 |  |  | 211 |  |  |  |  |
Veklury |  | 1,527 |  |  | 109 |  |  | 287 |  |  | 1,923 |  |  | 785 |  |  | 60 |  |  | 28 |  |  | 873 |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 35 |  |  | 12 |  |  | — |  |  | 47 |  |  | 5 |  |  | 4 |  |  | — |  |  | 9 |  |  |  |  |
Yescarta |  | 100 |  |  | 66 |  |  | 9 |  |  | 175 |  |  | 85 |  |  | 51 |  |  | 2 |  |  | 138 |  |  |  |  |
Total Cell Therapy |  | 135 |  |  | 78 |  |  | 9 |  |  | 222 |  |  | 90 |  |  | 55 |  |  | 2 |  |  | 147 |  |  |  |  |
Trodelvy |  | 100 |  |  | 1 |  |  | — |  |  | 101 |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 7 |  |  | 67 |  |  | 69 |  |  | 143 |  |  | 18 |  |  | 58 |  |  | 35 |  |  | 111 |  |  |  |  |
Letairis |  | 46 |  |  | — |  |  | — |  |  | 46 |  |  | 78 |  |  | — |  |  | — |  |  | 78 |  |  |  |  |
Zydelig |  | 6 |  |  | 7 |  |  | — |  |  | 13 |  |  | 8 |  |  | 9 |  |  | — |  |  | 17 |  |  |  |  |
Other(7) |  | 28 |  |  | 10 |  |  | 5 |  |  | 43 |  |  | 32 |  |  | 10 |  |  | 3 |  |  | 45 |  |  |  |  |
Total Other |  | 87 |  |  | 84 |  |  | 74 |  |  | 245 |  |  | 136 |  |  | 77 |  |  | 38 |  |  | 251 |  |  |  |  |
Total product sales |  | 5,479 |  |  | 997 |  |  | 880 |  |  | 7,356 |  |  | 5,076 |  |  | 877 |  |  | 540 |  |  | 6,493 |  |  |  |  |
Royalty, contract and other revenues |  | 30 |  |  | 34 |  |  | 1 |  |  | 65 |  |  | 24 |  |  | 60 |  |  | — |  |  | 84 |  |  |  |  |
Total revenues |  | $ | 5,509 |  |  | $ | 1,031 |  |  | $ | 881 |  |  | $ | 7,421 |  |  | $ | 5,100 |  |  | $ | 937 |  |  | $ | 540 |  |  | $ | 6,577 |  |  |  |  |
|  | Nine Months Ended September 30, 2021 |  | Nine Months Ended September 30, 2020 |  |  |  |
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total |  |  |  |
Product Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 96 |  |  | $ | 10 |  |  | $ | 12 |  |  | $ | 118 |  |  | $ | 275 |  |  | $ | 17 |  |  | $ | 19 |  |  | $ | 311 |  |  |  |  |
Biktarvy |  | 4,926 |  |  | 707 |  |  | 461 |  |  | 6,094 |  |  | 4,346 |  |  | 528 |  |  | 314 |  |  | 5,188 |  |  |  |  |
Complera/Eviplera |  | 73 |  |  | 104 |  |  | 12 |  |  | 189 |  |  | 77 |  |  | 124 |  |  | 17 |  |  | 218 |  |  |  |  |
Descovy |  | 994 |  |  | 128 |  |  | 105 |  |  | 1,227 |  |  | 1,124 |  |  | 156 |  |  | 103 |  |  | 1,383 |  |  |  |  |
Genvoya |  | 1,633 |  |  | 306 |  |  | 184 |  |  | 2,123 |  |  | 1,927 |  |  | 376 |  |  | 183 |  |  | 2,486 |  |  |  |  |
Odefsey |  | 773 |  |  | 336 |  |  | 39 |  |  | 1,148 |  |  | 851 |  |  | 341 |  |  | 36 |  |  | 1,228 |  |  |  |  |
Stribild |  | 94 |  |  | 33 |  |  | 12 |  |  | 139 |  |  | 100 |  |  | 42 |  |  | 12 |  |  | 154 |  |  |  |  |
Truvada |  | 268 |  |  | 18 |  |  | 24 |  |  | 310 |  |  | 1,245 |  |  | 20 |  |  | 37 |  |  | 1,302 |  |  |  |  |
Revenue share - Symtuza(1) |  | 261 |  |  | 125 |  |  | 8 |  |  | 394 |  |  | 244 |  |  | 112 |  |  | 6 |  |  | 362 |  |  |  |  |
Other HIV(2) |  | 14 |  |  | 9 |  |  | 12 |  |  | 35 |  |  | 24 |  |  | 4 |  |  | 21 |  |  | 49 |  |  |  |  |
Total HIV |  | 9,132 |  |  | 1,776 |  |  | 869 |  |  | 11,777 |  |  | 10,213 |  |  | 1,720 |  |  | 748 |  |  | 12,681 |  |  |  |  |
HCV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ledipasvir/Sofosbuvir(3) |  | 63 |  |  | 24 |  |  | 76 |  |  | 163 |  |  | 113 |  |  | 26 |  |  | 124 |  |  | 263 |  |  |  |  |
Sofosbuvir/Velpatasvir(4) |  | 649 |  |  | 234 |  |  | 272 |  |  | 1,155 |  |  | 646 |  |  | 253 |  |  | 330 |  |  | 1,229 |  |  |  |  |
Other HCV(5) |  | 97 |  |  | 64 |  |  | 9 |  |  | 170 |  |  | 100 |  |  | 37 |  |  | 12 |  |  | 149 |  |  |  |  |
Total HCV |  | 809 |  |  | 322 |  |  | 357 |  |  | 1,488 |  |  | 859 |  |  | 316 |  |  | 466 |  |  | 1,641 |  |  |  |  |
HBV / HDV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vemlidy |  | 266 |  |  | 25 |  |  | 298 |  |  | 589 |  |  | 248 |  |  | 22 |  |  | 194 |  |  | 464 |  |  |  |  |
Viread |  | 8 |  |  | 22 |  |  | 55 |  |  | 85 |  |  | 10 |  |  | 27 |  |  | 100 |  |  | 137 |  |  |  |  |
Other HBV/HDV(6) |  | 1 |  |  | 29 |  |  | — |  |  | 30 |  |  | 9 |  |  | 6 |  |  | — |  |  | 15 |  |  |  |  |
Total HBV/HDV |  | 275 |  |  | 76 |  |  | 353 |  |  | 704 |  |  | 267 |  |  | 55 |  |  | 294 |  |  | 616 |  |  |  |  |
Veklury |  | 2,763 |  |  | 761 |  |  | 684 |  |  | 4,208 |  |  | 785 |  |  | 60 |  |  | 28 |  |  | 873 |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 94 |  |  | 25 |  |  | — |  |  | 119 |  |  | 5 |  |  | 5 |  |  | — |  |  | 10 |  |  |  |  |
Yescarta |  | 300 |  |  | 188 |  |  | 25 |  |  | 513 |  |  | 283 |  |  | 144 |  |  | 7 |  |  | 434 |  |  |  |  |
Total Cell Therapy |  | 394 |  |  | 213 |  |  | 25 |  |  | 632 |  |  | 288 |  |  | 149 |  |  | 7 |  |  | 444 |  |  |  |  |
Trodelvy |  | 261 |  |  | 1 |  |  | — |  |  | 262 |  |  | — |  |  | — |  |  | — |  |  | — |  |  |  |  |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 32 |  |  | 202 |  |  | 186 |  |  | 420 |  |  | 46 |  |  | 166 |  |  | 113 |  |  | 325 |  |  |  |  |
Letairis |  | 157 |  |  | — |  |  | — |  |  | 157 |  |  | 241 |  |  | — |  |  | — |  |  | 241 |  |  |  |  |
Ranexa |  | 5 |  |  | — |  |  | — |  |  | 5 |  |  | 9 |  |  | — |  |  | — |  |  | 9 |  |  |  |  |
Zydelig |  | 22 |  |  | 27 |  |  | 1 |  |  | 50 |  |  | 24 |  |  | 30 |  |  | 1 |  |  | 55 |  |  |  |  |
Other(7) |  | 82 |  |  | 41 |  |  | 22 |  |  | 145 |  |  | 103 |  |  | 32 |  |  | 7 |  |  | 142 |  |  |  |  |
Total Other |  | 298 |  |  | 270 |  |  | 209 |  |  | 777 |  |  | 423 |  |  | 228 |  |  | 121 |  |  | 772 |  |  |  |  |
Total product sales |  | 13,932 |  |  | 3,419 |  |  | 2,497 |  |  | 19,848 |  |  | 12,835 |  |  | 2,528 |  |  | 1,664 |  |  | 17,027 |  |  |  |  |
Royalty, contract and other revenues |  | 70 |  |  | 140 |  |  | 3 |  |  | 213 |  |  | 55 |  |  | 170 |  |  | 16 |  |  | 241 |  |  |  |  |
Total revenues |  | $ | 14,002 |  |  | $ | 3,559 |  |  | $ | 2,500 |  |  | $ | 20,061 |  |  | $ | 12,890 |  |  | $ | 2,698 |  |  | $ | 1,680 |  |  | $ | 17,268 |  |  |  |  |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company. (2) Includes Emtriva and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston and Jyseleca. Revenues from Major Customers The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(as a percentage of total revenues) |  | 2021 |  | 2020 |  | 2021 |  | 2020
AmerisourceBergen Corporation |  | 25 | % |  | 30 | % |  | 24 | % |  | 25 | %
Cardinal Health, Inc. |  | 22 | % |  | 19 | % |  | 21 | % |  | 22 | %
McKesson Corporation |  | 21 | % |  | 22 | % |  | 18 | % |  | 22 | %
Revenues Recognized from Performance Obligations Satisfied in Prior Periods Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $190 million and $625 million for the three and nine months ended September 30, 2021, respectively, and $206 million and $618 million for the three and nine months ended September 30, 2020, respectively. Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $188 million and $661 million increase in revenues for the three and nine months ended September 30, 2021, respectively, and $13 million and $94 million increase in revenues for the three and nine months ended September 30, 2020, respectively. Contract Balances Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $167 million and $198 million as of September 30, 2021 and December 31, 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $85 million and $97 million as of September 30, 2021 and December 31, 2020, respectively. During the three and nine months ended September 30, 2021 and 2020, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration